A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.

ABSTRACT:

Background

Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of many cancers. However, the limited population that benefits from ICI therapy makes it necessary to screen predictive biomarkers for stratifying patients. Currently, many biomarkers, such as tumor mutational burden (TMB), have been used in the clinic as indicative biomarkers. However, some high-TMB patients with mutations in genes that are closely related to immunotherapeutic resistance are not sensitive to ICI therapy. Thus, there is a need to move beyond TMB and identify specific genetic determinants of the response to ICI therapy. In this study, we established a comprehensive mutation-based gene set across different tumor types to predict the efficacy of ICI therapy.

Methods

We constru

SUBMITTER: Long J 

PROVIDER: S-EPMC8867854 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature